The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 and explains why the post-pandemic future is looking bright for the UK industry.
As part of our series looking at how pharma companies have adapted to the pandemic, Shannon Rush, leader of Eli Lilly and Company's diabetes business unit in Northern Europe, tells pharmaph
A few months into the pandemic, the world is now moving beyond managing the crisis, with more focus on addressing the collateral damages and shaping the future.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.